A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET).
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2016
At a glance
- Drugs MK 2206 (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 22 Apr 2013 Planned end date changed from 1 Jul 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 18 Apr 2012 Planned End Date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.